Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 14/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662008 | 0.89 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4662488 | 0.88 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4987563 | 0.83 | CYP3A4 (0.79) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL6017786 | 0.83 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4663690 | 0.82 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL5656470 | 0.82 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL4662473 | 0.82 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4663628 | 0.80 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4663733 | 0.80 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL4663611 | 0.79 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033006-A1 | 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors | ALTANA PHARMA AG (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033006-A1 | 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors | CCKBR, GIPR, PGA5 | CYP3A4 314/4885CYP2C9 435/4885CYP2D6 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.